Imugene Limited (ASX:IMU) Receives $5.8m R&D Tax Refund
Financial Update
Imugene Limited (ASX: IMU) received a research and development tax refund of A$5,872,248, including A$84,990 in interest, for the 2024 financial year. The refund is part of the Australian Government’s R&D tax incentive, offering a refundable tax offset of up to 48.5%.
Operational Impact
The refund will support the further clinical development of Imugene’s immuno-oncology pipeline, including its CAR T drug azer-cel, various B-cell vaccine candidates, and the oncolytic virotherapy CF33.
Motley Fool contributor Lauren Surplice has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
